News from the Anastasia Khvorova Lab at UMass Chan Medical School

The siRNA-based therapy specifically targets photoreceptor cells in the eye, halting disease progression for six months to a year.

Technology developed at UMass Chan Medical School has been licensed by PLaN Therapeutics, a nonprofit biotechnology company owned by the PLN Foundation.

During the annual Recognition Ceremony, the Morningside Graduate School of Biomedical Sciences celebrated 74 PhD candidates and MD/PhD students who successfully completed their qualifying exam in 2024-2025.

UMass Chan Medical licenses exNA oligonucleotide technology to Hongene Biotech Corporation

The Morningside Graduate School of Biomedical Sciences at UMass Chan Medical School honored student scientists for outstanding research and leadership qualities on May 29.

A siRNA therapeutic for dermatological diseases developed at UMass Chan Medical School has entered the clinical trial phase.

Anastasia Khvorova, PhD, has been awarded the 2025 Else Kröner Fresenius Prize for Medical Research.

A biochemical breakthrough using simple carbon atoms by Ken Yamada, PhD, and Anastasia Khvorova, PhD, has dramatically improved the stability and efficacy of a potential oligonucleotide therapeutic platform in mice.

Natick resident and Stanford Online High School student Rebecca Ahn outperformed other local high school students in the final round of the competition on March 16.

Representatives from UMass Chan presented on several topics and career paths, including RNA Therapeutics Institute, ScienceLive, community and government relations, diversity and inclusion and media and arts in sciences.